LOX rises as a potential survival biomarker: A commentary on “Identification of LOX as a candidate prognostic biomarker in Glioblastoma multiforme” by Liu et al.

IF 5 2区医学 Q2 Medicine

Translational Oncology Pub Date : 2023-09-02 DOI:10.1016/j.tranon.2023.101777

Eduardo Silva-Pavez , Hery Urra

引用次数: 0

查看原文本刊更多论文

LOX作为一种潜在的生存生物标志物而上升：刘等对“LOX作为多形性胶质母细胞瘤候选预后生物标志物的鉴定”的评论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Oncology ONCOLOGY-

CiteScore

8.40

自引率

2.00%

发文量

314

审稿时长

54 days

期刊介绍： Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.